Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites

Authors

  • Thomas Sersté,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Hepato-Gastroenterologie, Hôpital Saint-Pierre, Bruxelles, Belgium
    Search for more papers by this author
  • Christian Melot,

    1. Service des Urgences, Hôpital Universitaire Erasme, Bruxelles, Belgium
    Search for more papers by this author
  • Claire Francoz,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Université Denis Diderot-Paris 7, Site Bichat, France
    Search for more papers by this author
  • François Durand,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Université Denis Diderot-Paris 7, Site Bichat, France
    Search for more papers by this author
  • Pierre-Emmanuel Rautou,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    Search for more papers by this author
  • Dominique Valla,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Université Denis Diderot-Paris 7, Site Bichat, France
    Search for more papers by this author
  • Richard Moreau,

    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Université Denis Diderot-Paris 7, Site Bichat, France
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Didier Lebrec

    Corresponding author
    1. Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France
    2. Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    3. Université Denis Diderot-Paris 7, Site Bichat, France
    • INSERM, Hôpital Beaujon, 110 Boulevard du Général Leclerc, 92118 Clichy, France
    Search for more papers by this author
    • These authors contributed equally to this work.


  • Richard Moreau received an Interface Institut National de la Santé et de la Recherche Médicale/Assistance Publique–Hôpitaux de Paris fellowship.

  • Potential conflict of interest: Nothing to report.

Abstract

Beta-blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta-blockers on long-term survival in patients with cirrhosis and refractory ascites. We performed a single-center, observational, case-only, prospective study of patients with cirrhosis and refractory ascites who did or did not receive beta-blockers for the prevention of gastrointestinal bleeding; 151 patients were included. The mean Model for End-Stage Liver Disease score was 18.8 ± 4.1. All patients regularly underwent large-volume paracentesis and intravenous albumin administration. Seventy-seven patients (51%) were treated with propranolol (113 ± 46 mg/day). The median follow-up for the whole group was 8 months. The median survival time was 10 months [95% confidence interval (CI) = 8-12 months]. The probability of survival at 1 year was 41% (95% CI = 33%-49%). The clinical characteristics and laboratory values at enrolment were not significantly different between patients who were receiving propranolol and those who were not. The median survival time was 20.0 months (95% CI = 4.8-35.2 months) in patients not treated with propranolol and 5.0 months (95% CI = 3.5-6.5 months) in those treated with propranolol (P = 0.0001). The 1-year probability of survival was significantly lower in patients who received propranolol [19% (95% CI = 9%-29%)] versus those who did not [64% (95% CI = 52%-76%), P < 0.0001]. The independent variables of mortality were Child-Pugh class C, hyponatremia and renal failure as causes of refractory ascites, and beta-blocker therapy. Conclusion: The use of beta-blockers is associated with poor survival in patients with refractory ascites. These results suggest that beta-blockers should be contraindicated in these patients. HEPATOLOGY 2010

Ancillary